Thomas Dayspring: A Decade on Repatha – Stable CAD, No Ischemic Events
Thomas Dayspring, Lipidologist at Early Medical, shared on LinkedIn:
”Anecdotal Study of 1 — Me — I have chronic stable CAD (CAC > 300 15 years ago). With that and other risk factors I had, I easily would have qualified for inclusion in the VESALIUS CV Trial. Fortunately, as soon as PCSK9i came on the market I went on Repatha and now a decade later I am still here – no ischemic events. The day after I got the CAC, I had an invasive coronary angiogram which demonstrated wide open lumens: disease was all in arterial wall. Here is data from GLACOV that shows evolocumab not only kept me alive without any CV issues but likely is causing regression. My apoB on Repatha monotherapy is 50 mg/dL and LDL-C 45 mg/dL. THANK YOU REPATHA, Amgen National Lipid Association European Atherosclerosis Society, American Society for Preventive Cardiology (ASPC).”
Stay updated with Hemostasis Today.
-
Aug 27, 2026, 00:14Join EHA ReCon 2027 in Malta – Explore RNA Biology to Therapeutics
-
Aug 27, 2026, 00:04John Cush: Registry Study Confirms Real-World Liver Risks with Avacopan
-
Aug 26, 2026, 23:57N. Mariana S. Vasquez: TTP vs ITP vs DIC
-
Aug 26, 2026, 23:49Mauricio Ambriz: Pathogenesis of Autoimmune Hemolytic Anemia Mediated by Warm and Cold Antibodies
-
Aug 26, 2026, 23:45Can Thromboinflammation Biomarkers Improve PE Mortality Prediction? – RPTH Journal
-
Aug 26, 2026, 23:44From Almost Universally Fatal to Largely Treatable iTTP – American Society of Hematology
-
Aug 26, 2026, 23:39Eric Topol: Shingles Vaccine Associated with 10% Drop in Heart Failure and Stroke
-
Aug 26, 2026, 22:59Debbe McCall: Should Frail Elderly Patients Stable on Warfarin Switch to DOACs?
-
Aug 26, 2026, 18:38Maia Meier: Muhiba’s Story of Courage, Resilience and Hope With Type 3 VWD